# A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)

> **NCT03842267** · PHASE3 · COMPLETED · sponsor: **LG Chem** · enrollment: 315 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Gemigliptin 50mg
- **DRUG:** Gemigliptin Placebo

## Key facts

- **NCT ID:** NCT03842267
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-13
- **Primary completion:** 2021-05-20
- **Final completion:** 2022-11-30
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842267, "A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03842267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*